vaccine for COVID-19, on the back of similar such review launches for vaccines from AstraZeneca and Pfizer."We just announced that the European Medicines Agency has begun a rolling review of mRNA-1273, our mRNA vaccine candidate against COVID-19," Moderna said in a tweet.Moderna Inc said on Monday its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage clinical trial, becoming the second U.S.
company in a week to report results that far exceed expectations.Last week, Pfizer and BioNTech said their vaccine candidate was more than 90% effective.The European Commission said that positive results announced by U.S.